Zantac Lawsuit

Zantac Ad - 3 Types of Zantac

The Food and Drug Administration requested the removal of Zantac, from the U.S. market in April 2020. The reason for the request was contamination with N-Nitrosodimethylamine (NDMA), which is classified as a probable carcinogen by the Environmental Protection Agency and the International Agency for Research on Cancer.

Call us today for a free consultation at 800-718-4658 if you or a loved one was diagnosed with cancer after using Zantac. You may be eligible for financial compensation, and we only collect a fee for our services if we obtain a recovery for you.

Do I Qualify For A Zantac Lawsuit?

You may be eligible to a financial recovery in a Zantac lawsuit if:

  • You have ingested over-the-counter, name-brand prescription, or generic prescription Zantac
  • You used Zantac for at least three months
  • You have been diagnosed with bladder, breast, colorectal, intestinal, esophageal, gastric, stomach, kidney, liver, lung pancreatic, or prostate cancer
  • You were under the age of 75 at the time of your cancer diagnosis
  • Your cancer diagnosis occurred at least three months after you started taking Zantac

Zantac Lawsuit Damages

Plaintiffs in Zantac lawsuits can obtain financial recoveries for many damages, including:

  • Past and future medical bills
  • Physical and mental pain and suffering
  • Loss of wages and loss of earning capacity
  • A loss of enjoyment of life
  • Loss of life (in a wrongful death lawsuit)
  • Punitive damages

Elements Of A Zantac Lawsuit

A Zantac lawsuit in California may recover damages based on several causes of action, including:

Strict Liability – Failure To Warn: Drug manufacturers are strictly liable for damages caused by their drugs in California when a drug’s known or knowable risks harm a consumer and the manufacturer fails to warn the consumer about the risks under CACI No. 1205.

Ranitidine experiment results were published by Dr. Silvio de Flora of the University of Genoa in 1981. These results noted “toxic and mutagenic effects” which happened when ranitidine was exposed to nitrates and human gastric fluid. Dr. de Flora noted these effects may have occurred because of the “formation of more than one nitroso derivative under our experimental conditions.” NDMA is a nitroso derivative.

The Lancet saw a response to these experimental results from GlaxoSmithKline (GSK) two weeks later. This response clearly demonstrates GSK was aware of the possibility that NDMA could be formed when ranitidine was exposed to human gastric fluid.

By 1987, many studies had demonstrated that ranitidine-containing products, like Zantac, had a problem with carcinogenic nitroso compounds. A lawsuit claims GSK responded to these studies with a “rigged” study that found no NDMA in the gastric contents of people who used ranitidine medication, such as Zantac. The lawsuit claims all gastric samples containing ranitidine were removed from the study, and that the study failed to use an accurate analytical system.

“Without the chemical being present in any sample, any degradation into NDMA could not, by design, be observed,” the lawsuit says, claiming GSK knew or should have known that the study was inadequate.

It has been known that NDMA is a probable carcinogen since at least 1979, when a news article claimed “NDMA has caused cancer in nearly every laboratory animal tested so far.” A lawsuit claims that consumer products with unsafe NDMA levels have been recalled by manufacturers as early as in 1980.

Zantac lawsuits may recover damages based on strict liability – failure to warn since it appears that the makers of Zantac knew it might contain NDMA, knew NDMA was dangerous and failed to warn consumers about the danger their product posed.

Strict Liability – Design Defect: Drug manufacturers are strictly liable for damages caused by their drugs in California when their drugs harm consumers because the drugs are dangerous when manufactured correctly by design under CACI No. 1203.

Testing lab Emery Pharma discovered that NDMA gradually forms over time in samples of ranitidine which are exposed to heat. The lab exposed a sample of ranitidine to a temperature of 158 degrees Fahrenheit. The sample exceeded the FDA’s daily intake limit for NDMA of 96 nanograms after only five days of exposure to this heat, and contained 142 nanograms of NDMA after 12 days. Emery exposed another sample of ranitidine to 77 degrees Fahrenheit and it contained 25 nanograms of NDMA after only 12 days.

This means that ranitidine, after only 48 days of storage in a 77 degree warehouse, could contain more NDMA than the FDA’s daily intake limit.

The fact that NDMA is forming in Zantac when Zantac is exposed to heat means that the source of the NDMA contamination doesn’t come from a manufacturing defect. Zantac (ranitidine) is defective by design because the probable carcinogen NDMA forms in it over time even when the drug is manufactured correctly, by design.

Zantac has also been linked to cancer and NDMA formation by more recent studies as well. A recent study found that Zantac used increased bladder cancer risk by 22%, and that taking Zantac for three years or more increased bladder cancer risk by 43%.

Negligence: A drug manufacturer in California is negligent under CACI No. 1221 when they fail to use the amount of care in making a product that a reasonably careful manufacturer would use in similar circumstances to avoid exposing others to a foreseeable risk of harm.

A reasonable drug manufacturer would warn consumers about a cancer risk if they knew or should have known that their drug could contain a probable carcinogen. Zantac lawsuits allege that Zantac makers knew their drugs could contain NDMA, knew NDMA was dangerous and failed to warn consumers about the danger. One lawsuit even accuses Zantac makers of “deliberately” refusing “to test Zantac products because they knew that the chemical posed serious health risks to humans.”

Zantac lawsuits may recover damages based on negligence because it is negligent to not warn consumers of a risk that you know or should know about.

Zantac Lawyers

Nationwide Representation | Red image of the USA

The dangerous drug specialists at Nadrich & Cohen have successfully resolved thousands of claims regarding the side effects of dangerous drugs. We have a history of six and seven figure recoveries in dangerous drug cases, including a $14,250,000 recovery for a 9-year-old girl who developed Stevens Johnson Syndrome after taking Children’s Motrin.

We are handling Zantac side effect cases throughout California and nationwide.

Our battle-tested attorneys offer a no fee promise, which means that we only charge a percentage of your recovery if and only if we obtain a recovery for you. No recovery, no fee.

Call us today at 800-718-4658 for a free consultation if you or a loved one took Zantac and was subsequently diagnosed with cancer. You may be eligible for a financial recovery. You can also use the live chat feature, email us at info@personalinjurylawcal.com or complete the contact form on this page.